Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Krystal Biotech, Inc. - Common Stock (NQ:KRYS)

370.15 -4.53 (-1.21%)
Streaming Delayed Price Updated: 10:31 AM EDT, Jul 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Krystal Biotech, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Unlocking a $750 Million Opportunity: Krystal Biotech's Vyjuvek and its Potent Impact on Dystrophic Epidermolysis Bullosa Treatment ↗
The FDA approved Krystal Biotech Inc's (NASDAQ: KRYS) Vyjuvek (beremagene geperpavec-svdt) for treating patients six months of age or older with  
Via Benzinga
News headline image
Why Shares of Krystal Biotech Are Rising Monday ↗
The company is moving quickly to market its newly approved therapy. 
Via The Motley Fool
Krystal Biotech Inc. (NASDAQ: KRYS) Highlighted for Surprising Price Action
Via Investor Brand Network
News headline image
Analyst Expectations for Krystal Biotech's Future ↗
 
Via Benzinga
News headline image
FDA Approves First Redosable Gene Therapy, Krystal Biotech's Treatment For Skin Blistering Disorder ↗
The FDA approved Krystal Biotech Inc's (NASDAQ: KRYS) Vyjuvek (beremagene geperpavec-svdt) for the treatment of patients six months of age or older with dystrophic  
Via Benzinga
News headline image
NVIDIA To Rally Around 22%? Here Are 10 Other Analyst Forecasts For Monday ↗
Needham cut the price target for Wix.com Ltd. (NASDAQ: WIX) from $125 to $120. Needham analyst Bernie McTernan maintained a Buy rating. Wix.com shares dropped 3.2% to close at $78.09 on Friday. 
Via Benzinga
News headline image
Expert Ratings for Krystal Biotech ↗
 
Via Benzinga
News headline image
Krystal Biotech Epidermolysis Bullosa Study Data Published In New England Journal Of Medicine ↗
 
Via Benzinga
News headline image
2 Risky Stocks That Could Soar in 2023 ↗
These "exciting" companies aren't for everyone. 
Via The Motley Fool
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2023 ↗
 
Via Benzinga
News headline image
Dentsply Sirona, Chico's FAS, Kontoor Brands And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded lower, with the Dow Jones dropping more than 150 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Krystal Biotech's Subsidiary Posts Durability Data For Fine Line, Wrinkles ↗
 
Via Benzinga
News headline image
Recap: Krystal Biotech Q3 Earnings ↗
Krystal Biotech (NASDAQ:KRYS) reported its Q3 earnings results on Monday, November 7, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023 ↗
 
Via Benzinga
News headline image
Have A Look At William Blair's Top Biotech Picks For 2023 ↗
William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period. 
Via Benzinga
News headline image
The 7 Hottest Biotech Stocks to Own in 2023 and Beyond ↗
Biotech is one of the safest, recession-proof sectors on the market. It's why we're going after the hottest biotech stocks in the New Year. 
Via InvestorPlace
News headline image
SolarEdge To Rally 54%? Plus This Analyst Predicts $1,335 For Mettler-Toledo International ↗
Goldman Sachs raised the price target on Mettler-Toledo International Inc. (NYSE: MTD) from $1,120 to $1,335. Goldman Sachs analyst Matthew Sykes upgraded the stock from Sell to Neutral. Mettler-Toledo... 
Via Benzinga
News headline image
Recap: Krystal Biotech Q4 Earnings ↗
Krystal Biotech (NASDAQ:KRYS) reported its Q4 earnings results on Monday, February 28, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
News headline image
Cigna To $335? Plus This Analyst Slashes PT On Six Flags Entertainment By 25% ↗
  SVB Leerink raised the price target on Cigna Corporation (NYSE: CI) from $305 to $335. Cigna shares rose 0.7% to close at $324.37 on Monday. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
FDA Accepts Krystal Biotech's Filing For Genetic Skin Disorder Candidate Under Priority Review ↗
The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ: KRYS) Biologics License Application (BLA) for its lead candidate B-VEC in the treatment of patients with... 
Via Benzinga
News headline image
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Recap Of Monday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Krystal Biotech Gets FDA Nod For Initial-Stage Lung Infection Study ↗
The United States Food and Drug Administration (FDA) has accepted Krystal Biotech’ (NASDAQ: KRYS) Investigational New Drug (IND) application to evaluate KB407 in a clinical trial for cystic fibrosis... 
Via Benzinga
News headline image
Krystal Biotech Files To Seek Approval For Skin Disease Candidate ↗
Krystal Biotech, Inc. (NASDAQ: KRYS) submits biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of B-VEC (beremagene geperpavec) in the treatment of... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Krystal Biotech Stock Sees Healthy Relative Strength Rating Upgrade ↗
On Thursday, Krystal Biotech stock had its Relative Strength (RS) Rating upgraded from to 93, up 88 a day ago. 
Via Investor's Business Daily
News headline image
BofA Bullish On This Gene Therapy Biotech Transitioning Into A Commercial Enterprise ↗
Krystal Biotech Inc (NASDAQ:KRYS) shares have po... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.